HRP20151021T1 - Formulacije na osnovi nalbufina i njihove uporabe - Google Patents
Formulacije na osnovi nalbufina i njihove uporabe Download PDFInfo
- Publication number
- HRP20151021T1 HRP20151021T1 HRP20151021TT HRP20151021T HRP20151021T1 HR P20151021 T1 HRP20151021 T1 HR P20151021T1 HR P20151021T T HRP20151021T T HR P20151021TT HR P20151021 T HRP20151021 T HR P20151021T HR P20151021 T1 HRP20151021 T1 HR P20151021T1
- Authority
- HR
- Croatia
- Prior art keywords
- nalbuphine
- pharmaceutical formulation
- oral pharmaceutical
- povidone
- hcl
- Prior art date
Links
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 title claims 7
- 229960000805 nalbuphine Drugs 0.000 title claims 7
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 7
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229940069328 povidone Drugs 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000000377 silicon dioxide Substances 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 229920003081 Povidone K 30 Polymers 0.000 claims 3
- 229960000913 crospovidone Drugs 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- 235000019634 flavors Nutrition 0.000 claims 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 claims 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims 1
- 235000013736 caramel Nutrition 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 30 mg, koja sadrži po masi:
- 4,69 % nalbufina/HCl,
- 54,58 % manitola,
- 37,8 % povidona,
- 2% krospovidona,
- 0,10 % koloidne anhidridne silike,
- 0,50 % natrijevog stearil-fumarata,
- 0,33 % talka.
2. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 30 mg, koja sadrži po masi:
- 18,65 % nalbufina/HCl,
- 48 % aglomeriranog α-laktoza-monohidrata (Tablettose® 80),
- 14 % mikrokristalne celuloze (Avicel® PH200),
- 4,50 % povidona,
- 2,25% krospovidona,
- 0,45 % koloidne anhidridne silike,
- 0,45 % magnezijevog stearata,
- 2,70 % talka,
- 9 % Sepifilm® LP014.
3. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 10 mg, koja sadrži po masi:
- 11,86 % nalbufina/HCl,
- 53,28 % aglomeriranog α-laktoza-monohidrata (Tablettose® 80),
- 18,43 % mikrokristalne celuloze (Avicel® PH200),
- 4,56 % povidona (PVP K30),
- 0,46 % silike (Aerosil® 200),
- 0,46 % magnezijevog stearata,
- 1,83 % talka,
- 9,13 % Sepifilm® LP014.
4. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 50 mg, koja sadrži po masi:
- 20,55 % nalbufina/HCl,
- 22,02 % laktoze,
- 47,53 % mikrokristalne celuloze (Avicel® PH200),
- 4,98 % povidona (PVP CL),
- 0,50 % magnezijevog stearata,
- 3,98 % arome,
- 0,44 % Sepifilm® IR777.
5. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku granulata od 10 mg, koji sadrži po masi:
- 1,99 % nalbufina/HCl,
- 27,80 % polietilen glikola (PEG 400),
- 21,29 % magnezijevog aluminosilikata (Neusilin® UFL2),
- 6,49 % povidona K30,
- 0,50 % talka,
- 3,69 % suklraloze (zaslađivača),
- 29,20 % arome za maskiranje okusa,
- 2,56 % okusa karamele,
- 6,49 % Sepifilm® LP014.
6. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 30 mg, koja sadrži po masi:
- 20,31 % nalbufina/HCl,
- 62,16 % aglomeriranog α-laktoza-monohidrata (Tablettose® 80),
- 6,65 % povidona (PVP K30),
- 2,38% krospovidona (Polyplasdone XL),
- 1,76 % mikrokristalne celuloze (Avicel® PH200),
- 0,10 % silike (Aerosil® 200),
- 0,48 % magnezijevog stearata,
- 1,92 % talka,
- 4,81 % Sepifilm® LP014.
7. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da ona odgovara prema bilo kojem od zahtjeva 1 do 6, te se takva upotrebljava u obradi bolova koji se generiraju putem liječenja ovisnosti od opijata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1056689A FR2963889B1 (fr) | 2010-08-20 | 2010-08-20 | Formulations a base de nalbuphine et leurs utilisations |
| PCT/FR2011/051929 WO2012022919A2 (fr) | 2010-08-20 | 2011-08-18 | Formulations à base de nalbuphine et leurs utilisations |
| EP11758519.0A EP2605757B1 (fr) | 2010-08-20 | 2011-08-18 | Formulations a base de nalbuphine et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151021T1 true HRP20151021T1 (hr) | 2015-11-06 |
Family
ID=43426302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151021TT HRP20151021T1 (hr) | 2010-08-20 | 2015-09-28 | Formulacije na osnovi nalbufina i njihove uporabe |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20130123294A1 (hr) |
| EP (1) | EP2605757B1 (hr) |
| JP (2) | JP2013534242A (hr) |
| KR (1) | KR101801424B1 (hr) |
| CN (1) | CN103025317B (hr) |
| AR (1) | AR082493A1 (hr) |
| AU (1) | AU2011290614B2 (hr) |
| BR (1) | BR112013004016A2 (hr) |
| CA (1) | CA2804333C (hr) |
| CL (1) | CL2013000477A1 (hr) |
| CY (1) | CY1116729T1 (hr) |
| DK (1) | DK2605757T3 (hr) |
| EA (1) | EA024945B1 (hr) |
| ES (1) | ES2548535T3 (hr) |
| FR (1) | FR2963889B1 (hr) |
| HR (1) | HRP20151021T1 (hr) |
| HU (1) | HUE027664T2 (hr) |
| IL (1) | IL224230A (hr) |
| MA (1) | MA34484B1 (hr) |
| MX (1) | MX354416B (hr) |
| NZ (1) | NZ605469A (hr) |
| PL (1) | PL2605757T3 (hr) |
| PT (1) | PT2605757E (hr) |
| RS (1) | RS54244B1 (hr) |
| SG (1) | SG187566A1 (hr) |
| SI (1) | SI2605757T1 (hr) |
| SM (1) | SMT201500257B (hr) |
| TW (1) | TWI522100B (hr) |
| UA (1) | UA110945C2 (hr) |
| WO (1) | WO2012022919A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2919903B1 (en) | 2012-11-14 | 2020-07-22 | W.R. Grace & CO. - CONN. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| NZ708371A (en) * | 2012-12-14 | 2020-05-29 | Trevi Therapeutics Inc | Methods for treating pruritus |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CN105560202B (zh) * | 2016-03-11 | 2019-05-24 | 广州玻思韬控释药业有限公司 | 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用 |
| MX2021000908A (es) * | 2018-07-23 | 2021-06-08 | Trevi Therapeutics Inc | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. |
| KR102664288B1 (ko) * | 2018-09-14 | 2024-05-09 | 케러 테라퓨틱스, 인코포레이티드 | 카파 오피오이드 수용체 효능제의 경구 제형 |
| CN115335072A (zh) | 2020-03-18 | 2022-11-11 | 卡拉治疗学股份有限公司 | κ阿片受体激动剂的寡糖配制品 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282215A (en) * | 1980-06-17 | 1981-08-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| US4477457A (en) * | 1982-10-28 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia using nalmetrene |
| US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| FI972718A0 (fi) | 1996-07-02 | 1997-06-24 | More Magic Software Mms Oy | Foerfaranden och arrangemang foer distribution av ett anvaendargraenssnitt |
| US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| WO2000024386A1 (en) | 1998-09-08 | 2000-05-04 | Theratech, Inc. | Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs |
| JP2001089373A (ja) * | 1999-09-24 | 2001-04-03 | Tanabe Seiyaku Co Ltd | 経口投与製剤 |
| KR100664479B1 (ko) * | 1999-12-08 | 2007-01-04 | 파마시아 코포레이션 | 발데콕시브 조성물 |
| KR20010107754A (ko) * | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| US6680067B2 (en) | 2001-11-26 | 2004-01-20 | Oliver Yoa-Pu Hu | Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same |
| RU2254852C1 (ru) | 2004-01-23 | 2005-06-27 | Ефим Давыдович Нежинский | Раствор для инъекций, обладающий выраженным анальгетическим действием, и способ его получения |
| PL2402005T3 (pl) * | 2005-08-24 | 2021-11-22 | Endo Pharmaceuticals Inc. | Formulacje nalbufiny o przedłużonym uwalnianiu |
| US8394812B2 (en) * | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| EA200802159A1 (ru) * | 2006-04-25 | 2009-06-30 | Михаил Викторович Воронков | Введение агониста-антагониста пациентам с опиоидной зависимостью |
| JP2010513325A (ja) * | 2006-12-21 | 2010-04-30 | アルファファーム ピーティーワイ リミテッド | 医薬組成物 |
| US20080207667A1 (en) * | 2007-02-23 | 2008-08-28 | Rhame Robert W | Use of nalbuphine and related compounds to treat symptoms of respiratory problems |
| EP2389159A1 (en) * | 2009-01-22 | 2011-11-30 | Noramco, Inc. | Process for preparing particles of opioids and compositions produced thereby |
| CA2775890C (en) * | 2009-09-30 | 2016-06-21 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
-
2010
- 2010-08-20 FR FR1056689A patent/FR2963889B1/fr not_active Expired - Fee Related
-
2011
- 2011-08-18 MX MX2013001985A patent/MX354416B/es active IP Right Grant
- 2011-08-18 EP EP11758519.0A patent/EP2605757B1/fr active Active
- 2011-08-18 KR KR1020137002467A patent/KR101801424B1/ko active IP Right Grant
- 2011-08-18 ES ES11758519.0T patent/ES2548535T3/es active Active
- 2011-08-18 PL PL11758519T patent/PL2605757T3/pl unknown
- 2011-08-18 RS RS20150601A patent/RS54244B1/en unknown
- 2011-08-18 EA EA201300258A patent/EA024945B1/ru not_active IP Right Cessation
- 2011-08-18 WO PCT/FR2011/051929 patent/WO2012022919A2/fr active Application Filing
- 2011-08-18 US US13/810,358 patent/US20130123294A1/en not_active Abandoned
- 2011-08-18 CA CA2804333A patent/CA2804333C/fr not_active Expired - Fee Related
- 2011-08-18 CN CN201180035176.5A patent/CN103025317B/zh not_active Expired - Fee Related
- 2011-08-18 HU HUE11758519A patent/HUE027664T2/en unknown
- 2011-08-18 MA MA35689A patent/MA34484B1/fr unknown
- 2011-08-18 NZ NZ605469A patent/NZ605469A/en not_active IP Right Cessation
- 2011-08-18 JP JP2013524474A patent/JP2013534242A/ja active Pending
- 2011-08-18 SG SG2013004379A patent/SG187566A1/en unknown
- 2011-08-18 PT PT117585190T patent/PT2605757E/pt unknown
- 2011-08-18 AU AU2011290614A patent/AU2011290614B2/en not_active Ceased
- 2011-08-18 BR BR112013004016A patent/BR112013004016A2/pt not_active IP Right Cessation
- 2011-08-18 UA UAA201303394A patent/UA110945C2/uk unknown
- 2011-08-18 SI SI201130612T patent/SI2605757T1/sl unknown
- 2011-08-18 DK DK11758519.0T patent/DK2605757T3/en active
- 2011-08-19 AR ARP110103019A patent/AR082493A1/es unknown
- 2011-08-19 TW TW100129750A patent/TWI522100B/zh not_active IP Right Cessation
-
2013
- 2013-01-15 IL IL224230A patent/IL224230A/en active IP Right Grant
- 2013-02-18 CL CL2013000477A patent/CL2013000477A1/es unknown
-
2015
- 2015-09-28 HR HRP20151021TT patent/HRP20151021T1/hr unknown
- 2015-09-29 CY CY20151100862T patent/CY1116729T1/el unknown
- 2015-10-20 SM SM201500257T patent/SMT201500257B/it unknown
-
2016
- 2016-04-20 JP JP2016084673A patent/JP6173521B2/ja not_active Expired - Fee Related
- 2016-06-01 US US15/170,033 patent/US10441585B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151021T1 (hr) | Formulacije na osnovi nalbufina i njihove uporabe | |
| US10653776B2 (en) | Compositions and methods for reducing overdose | |
| ES2660544T3 (es) | Liberación pulsátil de fármaco | |
| ES2659815T3 (es) | Administración inmediata/retardada de fármacos | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| JP4524502B2 (ja) | イミダフェナシン含有口腔内速崩壊性錠剤 | |
| JP2009114113A (ja) | 口腔内崩壊錠及びその製造方法 | |
| JP2009507048A5 (hr) | ||
| FI2508188T3 (fi) | Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita | |
| WO2010103544A4 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP2010522242A5 (hr) | ||
| CA2628200A1 (en) | Solid pharmaceutical compositions containing pregabalin | |
| YU19501A (sh) | Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu | |
| US20150250746A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| CN104220050A (zh) | 包含包封于硬胶囊中的多单元球状片剂(must)的复合制剂及其制备方法 | |
| US20150110880A1 (en) | Orally disintegrating tablet and production process therefor | |
| AR056824A1 (es) | Tableta de neramexano con matriz de liberacion modificada | |
| JP2012533565A5 (hr) | ||
| JP2017506624A5 (hr) | ||
| JP2019508464A (ja) | クロピドグレル及びアスピリンを含む複合製剤 | |
| JP2008531594A5 (hr) | ||
| US20120177735A1 (en) | Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
| KR101004205B1 (ko) | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 | |
| WO2012029838A1 (ja) | 口腔内崩壊錠 | |
| CA2889283A1 (en) | Prolonged-release diphenidol composition |